Universidad Complutense de Madrid
E-Prints Complutense

A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist

Impacto

Downloads

Downloads per month over past year

Jacob, Tali Fishman and Singh, Vijay and Dixit, Mudit and Ginsburg-Shmuel, Tamar and Fonseca Vázquez, Begoña and Pintor Just, Jesús and Youdim, Moussa B. H. and Major, Dan T. and Weinreb, Orly and Fischer, Bilha (2018) A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist. Purinergic Signalling, 14 (3). pp. 271-284. ISSN 1573-9538

[img] PDF
Restringido a Repository staff only

2MB

Official URL: https://doi.org/10.1007/s11302-018-9614-7




Abstract

Extracellular nucleotides can regulate the production/drainage of the aqueous humor via activation of P2 receptors, thus affecting the intraocular pressure (IOP). We evaluated 5-OMe-UDP(α-B), 1A, a potent P2Y6-receptor agonist, for reducing IOP and treating glaucoma. Cell viability in the presence of 1A was measured using [3-(4, 5-dimethyl-thiazol-2-yl) 2, 5-diphenyl-tetrazolium bromide] (MTT) assay in rabbit NPE ciliary non-pigmented and corneal epithelial cells, human retinoblastoma, and liver Huh7 cells. The effect of 1A on IOP was determined in acute glaucomatous rabbit hyaluronate model and phenol-induced chronic glaucomatous rabbit model. The origin of activity of 1A was investigated by generation of a homology model of hP2Y6-R and docking studies. 1A did not exert cytotoxic effects up to 100 mM vs. trusopt and timolol in MTT assay in ocular and liver cells. In normotensive rabbits, 100 μM 1A vs. xalatan, trusopt, and pilocarpine reduced IOP by 45 vs. 20–30%, respectively. In the phenol animal model, 1A (100 μM) showed reduction of IOP by 40 and 20%, following early and late administration, respectively. Docking results suggest that the high activity and selectivity of 1A is due to intramolecular interaction between Pα-BH3 and C5-OMe which positions 1A in a most favorable site inside the receptor. P2Y6-receptor agonist 1A effectively and safely reduces IOP in normotense, acute, and chronic glaucomatous rabbits, and hence may be suggested as a novel approach for the treatment of glaucoma.


Item Type:Article
Additional Information:

Electronic supplementary material
The online version of this article ( https://doi.org/10.1007/s11302-018-9614-7) contains supplementary material, which is available to authorized users.

Uncontrolled Keywords:Human P2Y6 receptor, P2Y6 receptor agonist, Glaucoma, Intraocular pressure; 5-OMe-uridine-5′-α-borano-diphosphate
Subjects:Sciences > Chemistry > Biochemistry
Medical sciences > Medicine > Ophtalmology
ID Code:50668
Deposited On:17 Jan 2019 15:23
Last Modified:17 Jan 2019 15:23

Origin of downloads

Repository Staff Only: item control page